| Name | Title | Contact Details |
|---|
Maxor is a leading pharmacy care solutions company dedicated to improving patient outcomes and lowering the total cost of care through our clinically integrated set of pharmacy care services. Our teams help optimize the pharmacy experience for patients, our customers, their employees, and members whether it`s through our customized pharmacy benefit offerings; providing access to prescription medications and therapies through our home delivery and specialty pharmacies; or delivering clinical and financial value with our end-to-end pharmacy management solutions. With a legacy of exceptional service and deep clinical and pharmacy expertise, Maxor has been a trusted partner enabling pharmacy care since 1926.
StretchLab is a unique wellness concept, offering customized assisted-stretch sessions in a comfortable group setting.
Altruista Health provides a suite of technology solutions that support collaborative, data-driven and person-centered approaches to population health management. Founded in 2007, Altruista Health has been recognized by Gartner as one of the fastest-growing care management technology companies serving complex care populations. Today, our solutions remove barriers to care, reduce avoidable healthcare expenses and improve health outcomes for more than 38 million people. Our GuidingCare™ platform is a web-based population health management system that enables health plans to maximize the value of their data and improve the quality of care for high-risk members. GuidingCare integrates data from a variety of systems, including medical and pharmacy claims, EMR/EHR, eligibility, HIEs and others, to power role-optimized workflow management tools for care coordination, quality improvement, care transitions management, utilization management, LTC/long term support services and more.
La Mesa Healthcare Center is a La Mesa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.